Cassani et al., 2015 - Google Patents
Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's diseaseCassani et al., 2015
View PDF- Document ID
- 8122908360484672469
- Author
- Cassani E
- Barichella M
- Cancello R
- Cavanna F
- Iorio L
- Cereda E
- Bolliri C
- Maria P
- Bianchi F
- Cestaro B
- Pezzoli G
- Publication year
- Publication venue
- Parkinsonism & related disorders
External Links
Snippet
Introduction Changes in the composition of gut microflora have been associated with an increase in chronic diseases. Indican urinary concentration is one of the most common and easily assessable markers of intestinal dysbiosis. Little information is available on intestinal …
- 206010061536 Parkinson's disease 0 title abstract description 90
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cassani et al. | Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's disease | |
Kong et al. | Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet | |
Myers et al. | The gut microbiome in psoriasis and psoriatic arthritis | |
Kang et al. | Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia | |
Solch et al. | Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: a systematic review | |
Basolo et al. | Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans | |
Berding et al. | Diet can impact microbiota composition in children with autism spectrum disorder | |
Schwarz et al. | Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response | |
Lindefeldt et al. | The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy | |
Friedman et al. | FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid | |
Bernstein | Psychological stress and depression: risk factors for IBD? | |
Nuzum et al. | Gut microbiota differences between healthy older adults and individuals with Parkinson’s disease: a systematic review | |
Wang et al. | Effect of probiotics on central nervous system functions in animals and humans: a systematic review | |
Thaiss et al. | Persistent microbiome alterations modulate the rate of post-dieting weight regain | |
Ghaisas et al. | Gut microbiome in health and disease: Linking the microbiome–gut–brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases | |
De Angelis et al. | Autism spectrum disorders and intestinal microbiota | |
Tamanai-Shacoori et al. | Roseburia spp.: a marker of health? | |
Halmos et al. | Diets that differ in their FODMAP content alter the colonic luminal microenvironment | |
Parthasarathy et al. | Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation | |
Dewulf et al. | Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women | |
Suez et al. | Artificial sweeteners induce glucose intolerance by altering the gut microbiota | |
Verdam et al. | Human intestinal microbiota composition is associated with local and systemic inflammation in obesity | |
Wang et al. | Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders | |
Monteleone et al. | Multi-omics data integration in anorexia nervosa patients before and after weight regain: A microbiome-metabolomics investigation | |
Sanz et al. | Understanding the role of gut microbes and probiotics in obesity: how far are we? |